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Abstract Tamm-Horsfall protein (THP) powerfully
inhibits calcium oxalate crystal aggregation, but structur-
ally abnormal THPs from recurrent calcium stone formers
may promote crystal aggregation. Therefore, increased uri-
nary excretion of abnormal THP might be of relevance in
nephrolithiasis. We studied 44 recurrent idiopathic calcium
stone formers with a positive family history of stone dis-
ease (RCSFfam) and 34 age- and sex-matched healthy con-
trols (C). Twenty-four-hour urinary THP excretion was
measured by enzyme linked immunosorbent assay. Struc-
tural properties of individually puriWed THPs were
obtained from analysis of elution patterns from a Sepharose
4B column. Sialic acid (SA) contents of native whole 24-h
urines, crude salt precipitates of native urines and individu-
ally puriWed THPs were measured. THP function was stud-
ied by measuring inhibition of CaOx crystal aggregation
in vitro (pH 5.7, 200 mM sodium chloride). Twenty-four-
hour urine excretion of THP was higher in RCSFfam
(44.0 § 4.0 mg/day) than in C (30.9 § 2.2 mg/day,
P = 0.015). Upon salt precipitation and lyophilization, elu-
tion from a Sepharose 4B column revealed one major peak
(peak A, cross-reacting with polyclonal anti-THP antibody)
and a second minor peak (peak B, not cross-reacting).
THPs from RCSFfam eluted later than those from C
(P = 0.021), and maximum width of THP peaks was higher
in RCSFfam than in C (P = 0.024). SA content was higher in
specimens from RCSFfam than from C, in native 24-h urines
(207.5 § 20.4 mg vs. 135.2 § 16.1 mg, P = 0.013) as well
as in crude salt precipitates of 24-h urines (10.4 § 0.5 mg
vs. 7.4 § 0.9 mg, P = 0.002) and in puriWed THPs
(75.3 § 9.3 g/mg vs. 48.8 § 9.8 g/mg THP, P = 0.043).
Finally, inhibition of calcium oxalate monohydrate crystal
aggregation by 40 mg/L of THP was lower in RCSFfam
(6.1 § 5.5%, range ¡62.0 to +84.2%) than in C
(24.9 § 6.0%, range ¡39.8 to +82.7%), P = 0.022, and
only 25 out of 44 (57%) THPs from RCSFfam were inhibi-
tory (positive inhibition value) vs. 25 out of 34 (74%) THPs
from C, P < 0.05. In conclusion, severely recurrent calcium
stone formers with a positive family history excrete more
THP than healthy controls, and their THP molecules elute
later from an analytical column and contain more SA. Such
increasingly aggregated THP molecules predispose to
exaggerated calcium oxalate crystal aggregation, an impor-
tant prerequisite for urinary stone formation.
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Introduction
Tamm-Horsfall protein (THP) is the most abundant urinary
protein in healthy humans [1, 2]. Over the years, THP has
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56 Urol Res (2007) 35:55–62been described as a regulator of intrarenal cytokines, a con-
tributor to tubulointerstitial renal disease, a trigger of cast
nephropathy in multiple myeloma and a natural defense
against bacterial infection in the urinary tract [1]. Most
recent studies have emphasized the role of THP as a general
defense factor against uropathogenic microorganisms,
especially type 1 Wmbriated Escherichia coli [3, 4]. THP
inhibits apoptosis and chemotaxis of isolated polymorpho-
nuclear leukocytes, whereas phagocytosis is stimulated [5].
In addition, for many years, THP has been known for its
involvement in urinary crystallization and stone formation.
This has most recently been emphasized by the demonstra-
tion of a dramatic increase in spontaneous calcium oxalate
crystal formation in THP knockout mice in comparison
with wild-type mice, at least under conditions of excessive
calcium and oxalate intake [6]. In human urine, crystal
nucleation occurs opportunistically and quite abundantly
[7], in normals and stone formers alike [8]. Whereas growth
of nucleated microcrystals, at least for calcium oxalate, is
too slow to produce particles of clinically relevant sizes, it
is by means of crystal aggregation that larger particles form
[7, 9]. Particle formation in the urinary tract occurs under
exquisite control of macromolecular modulators of crystal-
lization [10, 11], i.e., particles form as a result of intimate
interactions between newly forming inorganic crystal sur-
faces and organic macromolecules [10, 11]. In animal mod-
els, the synthesis of THP as well as other urinary
macromolecules by renal cells is increased upon exposure
to high oxalate concentrations or calcium oxalate crystals
[10]. By reversibly binding at newly forming crystal sur-
faces, THP strongly enhances electrostatic surface charge
and viscous binding forces, whereby it aVects the process of
crystal aggregation [11, 12].
However, controversy exists as to whether THP is a pro-
moter or an inhibitor of the aggregation of calcium oxalate
crystals in human stone formers. In vitro, urine-like con-
centrations of THP powerfully inhibit crystal aggregation
[11], but rising concentrations of calcium, sodium, hydro-
gen ions and of THP itself progressively decrease its inhib-
itory activity [12]. Under urine-like conditions of low pH
and high sodium concentration, some structurally abnormal
THPs from recurrent calcium stone formers even become
promoters of crystal aggregation in vitro [13, 14]. The
molecular basis of this abnormality, which may be inher-
ited [15], may involve posttranslational changes in glyco-
sylation, which determine the biologic activity of THP [1].
Indeed, reduced terminally linked sialic acid (SA) has been
found in a few stone former THPs [16].
Because high concentrations of THP molecules promote
crystal aggregation at high urinary concentrations of cal-
cium and/or sodium, increased urinary THP excretion rates
might be of pathophysiological relevance in nephrolithiasis.
However, we have demonstrated that urinary THP excretion
was not diVerent from normal subjects in non-selected
recurrent kidney stone formers [17]. Since THP abnormali-
ties may be inherited [15], the present study aimed at mea-
suring THP excretion in highly selected recurrent
idiopathic calcium renal stone formers with a positive fam-
ily history of stone disease (RCSFfam), in comparison with
healthy controls. Furthermore, we wanted to evaluate struc-
tural and functional properties of individually puriWed THP
molecules from RCSFfam and healthy controls.
Subjects and methods
Study subjects
A total of 78 subjects, 44 recurrent calcium stone formers
with a positive family history (RCSFfam), and 34 age- and
sex-matched controls (C), were studied. Except for one C
and one RCSFfam, no materials from subjects who had par-
ticipated in our previous study on THP abnormalities in cal-
cium oxalate nephrolithiasis [15] were used for the present
experiments. Out of 254 consecutive stone formers origi-
nally referred to the Renal Stone Clinic at the University of
Berne, Switzerland, for metabolic evaluation over a period
of 3.25 years, we identiWed 35 (13.8%), 31 men and four
women, with a positive family history for kidney stone dis-
ease (i.e., patients indicated a history of kidney stones in
parents, grandparents, siblings, uncles or aunts) and meet-
ing the following criteria: (1) recurrent calcium nephrolithi-
asis, i.e., passage from at least two calcium-containing
stones, deWned either by stone analysis (X-ray diVraction or
infrared spectroscopy) or disappearance of opaque material
on conventional radiographs; (2) idiopathic calcium stone
disease, i.e., patients with or without idiopathic hypercalci-
uria, hyperoxaluria, hyperuricosuria or hypocitraturia; (3)
normal renal function, i.e., plasma creatinine concentration
less than 115 mol/L. Nine additional patients (six men,
three women) meeting identical criteria were recruited from
the Kidney Stone Laboratory at the University of Chicago
for additional work-up of individual THP molecules.
Excluded were all patients who exhibited well-deWned
causes of hypercalciuria (primary hyperparathyroidism,
hypercalcemia associated with malignancy or immobiliza-
tion, excess intake of vitamin D, sarcoidosis, renal tubular
acidosis and medullary sponge disease), hyperoxaluria (pri-
mary hyperoxaluria, malabsorption with steatorrhea due to
inXammatory bowel disease or short bowel syndrome) or
hypocitraturia (renal tubular acidosis, malabsorption with
steatorrhea or chronic urinary tract infection). In total, 44
RCSFfam, 37 men and seven women, were selected for stud-
ies. Their mean age was 43.4 § 1.6 years (range 27–67),
and they were severely recurrent stone formers, having
formed a mean of 10.8 § 2.0 stones (range 2–50). All123
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of THP excretion, i.e., calcium, citrate and uric acid [17],
were discontinued at least 2 weeks before urine collection.
In comparison, a total of 34 controls (C), 25 men and
nine women, were studied. Twenty-six (21 men and Wve
women) control subjects were recruited from the University
of Berne, and eight (four men, four women) from the Kid-
ney Stone Laboratory of the University of Chicago. Their
mean age was 39.1 § 1.7 years (range 23–69), not diVerent
from RCSFfam. All control subjects were without a personal
or family history of renal stone formation and not were tak-
ing any medication interfering with urinary determinants of
THP excretion.
Experimental procedures
Table 1 summarizes all experimental procedures that are
outlined in detail in the subsequent paragraphs. Except for
24-h excretion rates of THP, routine 24-h urine chemistries
are not reported here, since the purpose of this study was to
investigate individual THP molecules irrespective of 24-h
urine compositions.
Measurements of urinary Tamm-Horsfall protein
For logistic reasons, 24-h excretion rates of urinary THP
were measured in only one 24-h urine specimen of all sub-
jects from the University of Berne (35 RCSFfam, 26 C). It
has to be acknowledged that the day-to-day variability for
THP in human urine amounts to 11% [18]. As previously
described [17], THP was measured by a commercially
available indirect non-competitive enzyme-linked immuno-
sorbent assay (Synelisa Tamm-Horsfall protein, Pharmacia
& Upjohn/Elias Diagnostics, Freiburg, Germany), whereby
monoclonal mouse anti-human THP antibodies, immobi-
lized on pins, bind THP antigen from standards (0–3.5–8–
20–50–120 mg/L in phosphate-buVered saline) and urine
samples. The antigen–antibody complexes associate with
an enzyme-labeled polyclonal sheep anti-human THP anti-
body, which subsequently converts added substrate to form
a colored solution, monitored at 492 nm.
Using this method, normal urinary excretion rates of
THP have been found to be 9.3–35.0 mg/day for men and
9.0–36.3 mg/day for women, respectively (5th–95th per-
centile). All freshly collected 24-h urines were carefully
shaken for 2 min at room temperature in order to avoid los-
ing large THP polymers for analysis due to settling. Imme-
diately thereafter, 10 L-aliquots were aspired and diluted
1:100 with the denaturing sample buVer supplied with the
ELISA kit. All incubations were carried out at room tem-
perature, and measurements were performed in duplicate.
CoeYcients of variation were 5.0–5.2% for intra-assay var-
iability and 7.8–9.2% for inter-assay variability.
PuriWcation/elution pattern of THPs
General procedure
From individual whole 24-h urines, THP was precipitated
by adding 0.58 M NaCl according to Fletcher et al. [19].
Salt precipitates were dialyzed three times for 24 h against
distilled water at 4°C and then lyophilized. This puriWed
material was subsequently dissolved in a solution contain-
ing 4 M urea and 0.02 M sodium phosphate, pH 6.8,
whereby urea was recrystallized from 70% ethanol before
use. Thereafter, the material was passed through a Sepha-
rose 4B column (Sepharose 4B, 2 cm £ 100 cm, Pharma-
cia, Switzerland), as previously described [13]. Eluates
were collected by an automated fraction collector (1.5 mL/
tube), and absorbance of fractions was measured at 277 nm
[14].
As demonstrated in Fig. 1 for two representative individ-
uals (one C, one RCSFfam), materials usually eluted as one
major peak (peak A) and a second minor peak (peak B).
Since only peak A material had originally cross-reacted in
an ELISA with a polyclonal anti-THP antibody raised in
rabbits (Biomedical Technologies, Stoughton, MA, USA),
all elution fractions from peaks A were pooled, subse-
quently lyophilized and stored at 4°C for further experi-
ments. For all individual eluates of THPs, maximum
absorbance (i.e., maximum height of peaks), fraction num-
bers at maximum absorbance (i.e., peak position) and num-
bers of fractions from the beginning to the end of peaks
(i.e., maximum width of peaks) on elution diagrams were
Table 1 Summary of experimental procedures applied and materials
used throughout the study. For details, see Sect. “Subjects and meth-
ods”
THP measurements (ELISA):
- Native 24-h urines (35 RCSFfam and 26 C)
Chromatography (24-h urines of all 78 study subjects):
Whole urines + 0.58 M Nacl ) centrifugation 
) dialysis against H2O (3 x) ) lyophilization 
+ 4 M Urea/0.02 Na-Phospate ) passage through Sepharose 
4B column ) lyophilization of major peak A (= THP) + 
minor peak B
Cross-reaction with THP antibody:
-Peaks A and B (materials from 7 RCSFfam and 7 C)
Sialic acid determination by acid hydrolysis:
-Native 24-h urines (35 RCSFfam and 26 C)
-Crude salt precipitates of 24-h urines (35 RCSFfam and 26 C)
-ALL 78 peak A lyophilizates (= THP)
-17 peak B lyophilizates (9 RCSF and 8 C)
Crystal aggregation inhibition in vitro:
-40 mg/l of all 78 lyophilized THPs (peak A) at pH 5.7, 200 mM 
Nacl123
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rough estimate of the amount of eluted THP.
Sialic acid measurements
Sialic acid was measured using the thiobarbituric assay
described by AminoV [20]. BrieXy, after oxidation with
periodic acid (25 mM in 0.125 N H2SO4, pH 1.2) and
reduction of excess periodate with sodium arsenite (2 vol%
in 0.5 N HCl), 2-thiobarbituric acid (0.1 M aqueous solu-
tion, pH 9.0) is added and heated for 7.5 min in a boiling
water bath. The colored solution is cooled on ice, followed
by extraction with acid butanol (butan-1-ol, addition of 5
vol% 12 N HCl). The absorbance at 549 nm in the butanol
layer is directly proportional to the SA concentration, with
a molar extinction of 70.7 £ 103 [20]. A calibration curve
was constructed by using 5–40 g of N-acetyl-neuraminic
acid in aqueous solution.
The SA content was measured in four types of speci-
mens (Table 1).
Native 24-h urines
A sample of 0.5 mL of native 24-h urine was directly used
for the thiobarbituric assay, as described above. The
amount of SA in whole 24-h urines was obtained from
extrapolating the SA content in 0.5 mL whole urine to the
respective 24-volume. This was performed in native urines
of all subjects from the University of Berne.
Crude salt-precipitates of 24-h urines
To 20 mL of native 24-h urines, 0.58 M NaCl (0.68 g) was
added. After stirring overnight and centrifugation at
5,000 rpm for 15 min, precipitates were separated from
supernatants. Precipitates were then brought back to their
original volume by adding distilled H2O. In order to make
sure that precipitates were richer in THP than supernatants,
as assumed, we measured THP concentrations both in
supernatants and precipitates from 22 subjects (11 RCSF,
11 C) by ELISA (described above) in a preliminary study.
THP concentrations amounted to 15.5 § 2.3 mg/L in pre-
cipitates and 1.9 § 0.3 mg/L in supernatants, respectively
(P = 0.0001), thus proving that major amounts of THP were
present in precipitates. Therefore, SA contents were subse-
quently determined in crude salt precipitates of all 24-h
urines from subjects of the University of Berne.
Hydrolysis of precipitates was performed by adding
50 mM H2SO4 and incubating at 80°C for 60 min. Thereaf-
ter, pH was adjusted to 5.5. After dialysis against 30 mL of
H2O for 24 h, diVusates were lyophilized and then redis-
solved in 1 mL water. In 0.5 mL of this solution, SA con-
tent was measured according to AminoV [20] as described
above, and the amount of SA in the precipitate of the whole
24-h urine was calculated.
PuriWed THPs (peaks A eluting from Sepharose 4B column)
Two milligrams of all lyophilized THPs (major peak A, see
above) were dissolved in 2 mL of 50 mM H2SO4 overnight.
Undissolved material was removed by centrifugation at
3,000 rpm for 10 min. Thereafter, THP concentration in
solution was measured by the extinction at 277 nm [13, 14].
Hydrolysis was then obtained by incubating 1 mL of this
THP solution at 80°C for 60 min. After adjustment of the
pH to 5.5, the sample was dialyzed for 24 h against 30 mL
of H2O, and the diVusate was lyophilized. The lyophilisates
were redissolved in 1 mL of H2O, and SA content was
determined in 0.5 mL of this solution as described above.
Subsequently, the SA content per milligram of lyophilized
THP was calculated.
Second peaks (peaks B eluting from the Sepharose 
4B column)
Of original salt precipitates from subjects recruited at the
University of Chicago, material eluting as second peak
(peak B) was additionally pooled and lyophilized, and the
SA content per milligram of this material was also calcu-
lated.
Measurements of calcium oxalate crystal aggregation
The aggregation of calcium oxalate monohydrate (COM)
crystals in vitro was measured as previously described in
detail [13–15]. BrieXy, COM crystals (0.7 mg/mL) in a
solution containing 200 mM NaCl and 10 mM sodium ace-
tate, pH 5.70, are stirred overnight at 37°C under constant
stirring (850 rpm) in order to obtain a homogeneous slurry.
After preincubation with small amounts (<5 vol%) of aque-
Fig. 1 Elution patters of salted-out and dialyzed/lyophilized materials
on a Sepharose 4B column (two representative individuals, one C and




































Urol Res (2007) 35:55–62 59ous solutions of THPs in order to reach Wnal assay concen-
trations of 40 mg/L, additional particle aggregation is
induced with stirring at slower speed (500 rpm) for 180 s in
a spectrophotometric cuvette [13–15]. Thereafter, sponta-
neous particle sedimentation is monitored at 620 nm,
whereby the rate of decrease of absorbance at 620 nm over
time, called turbidity slope TS, reXects particle size [13–15].
The TS values in control slurries (TSC) are taken as 100%
aggregation, and percent crystal aggregation in presence of
THPs is calculated as (TS/TSC) £ 100. Percent inhibition of
COM crystal aggregation is calculated as 100% ¡ % aggre-
gation, whereby a negative inhibitory activity indicates pro-
motion of COM crystal aggregation [13–15].
Crystal aggregation experiments were performed in the
presence of 40 mg/L lyophilized and dissolved THP (peak
A material, see above) of all 78 study subjects.
Statistics
All values are presented as mean § SE. For comparisons
between groups, non-parametric Mann–Whitney U-test was
used, whereas Wilcoxon signed-rank test was applied for
within-group comparisons, and observed frequencies were
compared by 2 statistics. Simple and multiple linear
regression analysis was performed for correlation studies.
Results
Measurements of urinary Tamm-Horsfall protein
As shown in Fig. 2, 24-h urine excretion rate of THP was
higher in RCSFfam (44.0 § 4.0 mg/day) than in C
(30.9 § 2.2 mg/day, P = 0.015). When considering all 61
subjects in whom urinary THP had been measured (35
RCSFfam, 26 C), THP excretion rate was positively corre-
lated with the amount of SA detected in crude salt precipi-
tates of whole 24-h urines (see below), R = 0.565,
P = 0.0001. This correlation also persisted when calculated
separately for RCSFfam (R = 0.691, P = 0.0001) and C
(R = 0.490, P = 0.011), respectively.
PuriWcation/elution pattern of THPs
As depicted in Fig. 1 for two representative individuals,
elution from the column was delayed in THPs (peaks A)
from RCSFfam (fraction number at maximum absorbance
53.5 § 2.1) in comparison with THPs from C (46.1 § 1.9,
P = 0.021). The maximum peak absorbance was not diVer-
ent between RCSFfam (0.267 § 0.067) and C
(0.244 § 0.020). However, maximum width of peaks A,
i.e., number of fractions from the beginning to the end of
the eluted peak A material—a rough measure of the amount
of eluted THP—was higher in RCSFfam (45.1 § 3.4) than
in C (34.5 § 2.0, P = 0.024). The higher amounts of THP
daily excreted in urine by RCSFfam, as measured by ELISA
(Fig. 2), were marginally and positively correlated with the
widths of peak A (R = 0.255, P = 0.049).
For peak B materials, there was a trend for coming oV
the column later in RCSFfam (fraction number at maximum
absorbance 114.4 § 3.6) than in C (fraction number
107.4 § 3.8), and maximum absorbance of peaks B tended
to be lower in RCSFfam (0.137 § 0.050) than in C
(0.159 § 0.064, P = 0.072).
Sialic acid measurements
Figure 3 depicts the results of SA measurements. In native
whole 24-h urines (Fig. 3 a), the total amount of SA
excreted in urines from healthy controls was 135.2 §
16.1 mg/24 h, lower than in RCSFfam who excreted
207.5 § 20.4 mg/24 h (P = 0.013). SA contents in crude
salt precipitates of 24-h urines, presumably THP, were
7.4 § 0.9 mg/24 h in controls and 10.4 § 0.5 mg/24 h in
RCSFfam (P = 0.002, Fig. 3b, left). Measured in lyophili-
sates of peaks A (=THP), the SA content was
48.8 § 9.8 g/mg THP in C, signiWcantly lower than in
RCSFfam (75.3 § 9.3 g/mg THP, P = 0.043, Fig. 3b,
right). The amount of THP daily excreted in urine was pos-
itively related to the amount of SA detected in crude salt
precipitates of urines (presumably THP), R = 0.565,
P = 0.0001.
Sialic acid content of peak B material, measured in
selected subjects recruited at the University of Chicago
(seven C, seven RCSFfam), again tended to be lower in C
(47.6 § 15.8 g/mg) than in RCSFfam (63.0 § 27.4 g/mg
of protein, NS).
Measurements of calcium oxalate crystal aggregation
Values of inhibitory activity toward COM crystal aggrega-
tion by 40 mg/L of THP widely overlapped between pro-
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(range ¡62.0 to +84.2%), but were signiWcantly higher for
THPs from C (24.9 § 6.0%) than from RCSFfam
(¡6.1 § 5.5%, P = 0.022 vs. control THPs), as depicted in
Fig. 4. Under the experimental conditions of the present
study (pH 5.70, 200 mM NaCl), 25 out of 34 (73.5%) THPs
from controls were inhibitory, compared with 25 out of 44
THPs (56.8%) from RCSFfam (2 = 4.84, P < 0.05). Crystal
aggregation measurements were not signiWcantly related to
any of the analytical measures, i.e., THP excretion rates,
SA measurements or electrophoretic patterns, neither in
RCSFfam nor in C.
Discussion
This study demonstrates that every seventh patient with
recurrent idiopathic calcium renal stone disease referred to
our stone clinic had a positive family history, deWned as
history of kidney stones in parents, grandparents, siblings,
uncles or aunts (RCSFfam). The study represents the largest
investigation on urinary THP in a group of such highly
selected RCSFfam. Our main Wndings are that (1) RCSFfam
excrete signiWcantly more THP than age-matched controls,
(2) THPs from RCSFfam and C are structurally diVerent, as
demonstrated by elution patterns from an analytical column
and SA measurements and (3) THP molecules from RCSF-
fam are weaker inhibtors of calcium oxalate crystal aggrega-
tion than normal THPs.
Several studies have looked at urinary excretion rates of
THP in kidney stone formers and healthy controls. In stud-
ies using quantitative electroimmunodiVusion, THP excre-
tion rates were 40–50 mg/day, without diVerences between
stone formers and healthy subjects [21, 22]. More recent
studies used radioimmunoassay or ELISA and demon-
strated that THP excretion rates varied more widely among
subjects, generally ranging between 10 and 70 mg/day [17,
23–26]. THP excretion rates were either equal to healthy
controls [23, 24] or reduced in “common” stone formers
[17, 25, 26]. The latter was at least partly due to the fact
that some studies included uric acid stone formers in whom
ELISA measurements have indicated lower THP excretions
rates [17, 27]. The increased amounts of urinary THP mea-
sured in RCSFfam in the present study may reXect a truly
increased renal THP production. However, they might also
result from an increased number of THP-binding sites
exposed to the THP antibody, due to conformational
changes in proteins from RCSFfam.
Indeed, conformational alterations appear to be opera-
tional, as suggested by the delayed elution of lyophilized
stone former THPs from a Sepharose column. A very simi-
lar pattern was found in a small number of stone formers in
a previous study where delayed elution from a Sephacryl S-
200 column in THPs from stone formers, but not from
healthy controls, occurred [15]. Apparently, THP mole-
cules after salting-out from whole urine occur in at least
two diVerent states of molecular aggregation, and urines of
RCSFfam contain relatively more aggregated THP which
predisposes to delayed elution from an analytical column.
These Wndings are in keeping with our previous work dem-
onstrating increased viscosities and higher apparent molec-
ular masses of stone former THP isolated from whole urine
under the same experimental conditions [14, 15].
The role of SA content of THP molecules with respect to
urinary stone formation has been addressed previously.
Knörle et al. [16] compared individually puriWed THPs
from ten healthy controls and ten recurrent calcium oxalate
stone formers and found that stone formers’ THPs con-
tained signiWcantly less SA. Similar Wndings were most
recently obtained by Sumitra et al. [28], who compared 100
controls and 200 not-further-speciWed hyperoxaluric renal
stone formers. Using the same thiobarbituric assay, we
measured 49 § 10 g/mg THP in controls, identical to the
51 § 9 g/kg and the 50 § 6 g/mg THP obtained in healthy
Fig. 3 Results of sialic acid measurements in whole native 24-h urines
(a) as well as crude salt precipitates from whole urines and salt-precip-





















Fig. 4 Inhibition of calcium oxalate monohydrate crystal aggregation
in vitro by 40 mg/L of puriWed THP at pH 5.70 and 200 mM NaCl. For
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respectively. DiVerences between these studies and our
investigation, however, exist in stone former THPs: SA
content of THP in our highly selected RCSFfam was
75 § 9 g/mg THP, higher than the 21 § 4 g/kg in the ten
stone formers of Knörle et al. [16] and the 28 § 3 g/mg in
the 200 hyperoxaluric stone formers of Sumitra et al. [28].
We did not obtain data on SA contents of THPs from “ordi-
nary” calcium stone formers without positive family his-
tory, but based on the identical SA contents of normal
THPs in three diVerent studies [16, 28, present work], the
diVerence in SA content of stone former THPs between our
study and the studies by Knörle et al. [16] and Sumitra et al.
[28] is highly unlikely to be due to analytical diVerences. It
may rather reXect a speciWc molecular abnormality of THP
in our highly selected recurrent calcium stone formers with
positive family history.
This study conWrms once more that aggregation of COM
crystals is modulated by the presence of THP at physiologic
concentrations. Furthermore, we again Wnd reduced crystal
aggregation inhibition or even aggregation promotion by
THPs from recurrent stone formers, at least under condi-
tions of physiologically high ionic strength at solution pH
5.7 [14, 15]. Previous data indicated that THP function, i.e.,
crystal aggregation inhibition, was signiWcantly related to
THP structure, assessed by measurements of intrinsic vis-
cosity [14]. In the present study, we did not Wnd a correla-
tion between THP function and structural data, i.e., elution
patterns of THP molecules. Most likely, intrinsic viscosity
is a more accurate index of molecular THP conformation
with respect to THP interaction with urinary crystals.
At this point, it has to be emphasized that human urine
contains many molecules which act as modulators of crys-
tallization [29]. Obviously, one single molecule such as
THP cannot be considered fully responsible for all modula-
tory actions on urinary crystallization and crystal retention.
Furthermore, interactions between various crystallization
modulators, as demonstrated for instance for citrate and
THP [14, 24], ought to be considered; this was beyond the
scope of the present study. Moreover, animal models and
renal cell culture studies show increased synthesis of THP
as well as of other inhibitory macromolecules on exposure
to high oxalate and/or calcium oxalate crystals [10, 29]. It
therefore seems reasonable to envision that intermittent
high peaks of urinary oxalate concentrations (for instance
after meals), although not detected by routine 24-h urine
analysis, may induce a rise in the synthesis of potentially
“harmful” macromolecules such as THP in genetically pre-
disposed individuals.
In conclusion, our study conWrms that THP plays a role in
calcium oxalate crystal aggregation and in the formation of
calcium oxalate stones. We demonstrate for the Wrst time that
severely recurrent idiopathic calcium stone formers with a
positive family history excrete signiWcantly higher amounts
of structurally diVerent THP molecules with higher SA con-
tents than age-matched healthy controls. These abnormal
stone former THPs are less inhibitory or even promotive
toward calcium oxalate crystal aggregation, apparently one
of the more important prerequisites for urinary stone forma-
tion [7–9]. One can only speculate about the possibility that
such abnormal urinary macromolecules might also facilitate
the deposition of urinary crystal aggregates on preformed
Randall’s plaques in the ducts of Bellini [30].
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